<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28865459</article-id><article-id pub-id-type="pmc">5581407</article-id><article-id pub-id-type="publisher-id">1947</article-id><article-id pub-id-type="doi">10.1186/s12906-017-1947-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Clinical efficacy and IL-17 targeting mechanism of <italic>Indigo naturalis</italic> as a topical agent in moderate psoriasis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Hui-Man</given-names></name><address><email>hm.cheng@msa.hinet.net</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Yang-Chang</given-names></name><address><email>yachwu@mail.cmu.edu.tw</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qingmin</given-names></name><address><email>QWang2@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Michael</given-names></name><address><email>KSong18@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jackson</given-names></name><address><email>chhswu@tmu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Dion</given-names></name><address><email>DChen97@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Katherine</given-names></name><address><email>KLi@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wadman</surname><given-names>Eric</given-names></name><address><email>EWadman@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kao</surname><given-names>Shung-Te</given-names></name><address><email>stkao@mail.cmu.edu.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Tsai-Chung</given-names></name><address><email>tcli@mail.cmu.edu.tw</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Leon</surname><given-names>Francisco</given-names></name><address><email>fleon@celimmune.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hayden</surname><given-names>Karen</given-names></name><address><email>KHayden1@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Brodmerkel</surname><given-names>Carrie</given-names></name><address><email>CBrodmer@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chris Huang</surname><given-names>C.</given-names></name><address><phone>(215) 793-7509</phone><email>CHuang4@its.jnj.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Department of Integration of Traditional Chinese and Western Medicine, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution>School of Chinese Medicine, College of Chinese Medicine, China Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Chinese Medicine Research and Development Center, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff5"><label>5</label>Janssen Research &#x00026; Development, LLC, Spring House, PA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution>College of Pharmacy, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution>Department of Internal Chinese Medicine, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution>Department of Public Health, </institution><institution>College of Public Health, China Medical University, </institution></institution-wrap>Taichung, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>439</elocation-id><history><date date-type="received"><day>22</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">
<italic>Indigo naturalis</italic> is a Traditional Chinese Medicine (TCM) ingredient long-recognized as a therapy for several inflammatory conditions, including psoriasis. However, its mechanism is unknown due to lack of knowledge about the responsible chemical entity. We took a different approach to this challenge by investigating the molecular profile of <italic>Indigo naturalis</italic> treatment and impacted pathways.</p></sec><sec><title>Methods</title><p id="Par2">A randomized, double-blind, placebo-controlled clinical study was conducted using <italic>Indigo naturalis</italic> as topical monotherapy to treat moderate plaque psoriasis in a Chinese cohort (<italic>n</italic>&#x000a0;=&#x000a0;24). Patients were treated with <italic>Indigo naturalis</italic> ointment (<italic>n</italic>&#x000a0;=&#x000a0;16) or matched placebo (<italic>n</italic>&#x000a0;=&#x000a0;8) twice daily for 8&#x000a0;weeks, with 1 week of follow-up.</p></sec><sec><title>Results</title><p id="Par3">At week 8, significant improvements in Psoriasis Area and Severity Index (PASI) scores from baseline were observed in <italic>Indigo naturalis</italic>-treated patients (56.3% had 75% improvement [PASI 75] response) compared with placebo (0.0%). A gene expression signature of moderate psoriasis was established from baseline skin biopsies, which included the up-regulation of the interleukin (IL)-17 pathway as a key component; <italic>Indigo naturalis</italic> treatment resulted in most of these signature genes returning toward normal, including down-regulation of the&#x000a0;IL-17 pathway. Using an in vitro keratinocyte assay, an IL-17-inhibitory effect was observed for tryptanthrin, a component of <italic>Indigo naturalis</italic>.</p></sec><sec><title>Conclusions</title><p id="Par4">This study demonstrated the clinical efficacy of <italic>Indigo naturalis</italic> in moderate psoriasis, and exemplified a novel experimental medicine approach to understand TCM targeting mechanisms.</p></sec><sec><title>Trial registration</title><p id="Par5">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01901705?term=NCT01901705&#x00026;rank=1">NCT01901705</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12906-017-1947-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Indigo naturalis</italic></kwd><kwd>Gene expression</kwd><kwd>Mechanism of action</kwd><kwd>Psoriasis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005205</institution-id><institution>Janssen Research and Development</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007300</institution-id><institution>China Medical University</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">Psoriasis is a chronic inflammatory skin disease afflicting 1&#x02013;3% of the world&#x02019;s population [<xref ref-type="bibr" rid="CR1">1</xref>] and 0.12&#x02013;0.47% of the Chinese population [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Psoriasis is characterized by hyperproliferation of keratinocytes and dermal infiltration by activated T cells, neutrophils, and dendritic cells. The infiltrated psoriatic lesions have significantly increased levels of the CD4 T-cell subsets T helper (Th)1 and Th17 [<xref ref-type="bibr" rid="CR5">5</xref>]. Clinical studies have shown that neutralizing tumor necrosis factor-alpha (TNF-&#x003b1;), interleukin (IL)-12/23, or IL-17A is efficacious, demonstrating the central role of Th1/Th17 cells in psoriasis pathogenesis [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Several classes of therapy are available to treat patients with psoriasis including topical agents (e.g., corticosteroids, vitamin D<sub>3</sub>, salicylic acid, retinoids) and systemic agents (e.g., methotrexate, acitretin, cyclosporine, biologics). Topicals are regularly used as first-line options to treat mild-to-moderate psoriasis; however, long-term use of topical agents, such as corticosteroids, has been associated with adverse events such as atrophy and striae formation [<xref ref-type="bibr" rid="CR13">13</xref>]. Despite the availability of these treatments, topical Traditional Chinese Medicines (TCM), with <italic>Indigo naturalis</italic> as a key component, are commonly used as alternate therapies, especially in the Asia Pacific region [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par13">
<italic>Indigo naturalis</italic>, a Chinese herb known as Qing Dai, is a dried pigment prepared from several plant species including <italic>Baphicacanthus cusia</italic>. Recently, clinical studies have demonstrated that <italic>Indigo naturalis</italic> used as topical monotherapy is efficacious in treating patients with mild-to-moderate psoriasis [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>], although the validity of these studies is challenged by intra-patient treatment comparison designs [<xref ref-type="bibr" rid="CR23">23</xref>]. One component of <italic>Indigo naturalis</italic>, indirubin, was reported to inhibit cyclin-dependent kinase [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and signal transducer and activator of transcription-3 (STAT3) activities [<xref ref-type="bibr" rid="CR26">26</xref>], and keratinocyte proliferation in vitro [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Another compound, tryptanthrin, was reported to inhibit interferon-&#x003b3; production by lymphocytes from Peyer&#x02019;s Patches [<xref ref-type="bibr" rid="CR28">28</xref>], and nitric oxide and prostaglandin E2 synthesis by murine macrophages [<xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, <italic>Indigo naturalis</italic> extract has been shown to inhibit oxygen generation and elastase release in formyl-methionyl-leucyl-phenylalanine-induced human neutrophils in vitro [<xref ref-type="bibr" rid="CR21">21</xref>]. Still, as with most TCM, the therapeutically- active chemical entities of <italic>Indigo naturalis</italic> are poorly defined. Other plant extracts have also been investigated as topical agents for the treatment of psoriasis in controlled clinical trials [<xref ref-type="bibr" rid="CR30">30</xref>], including a topical cream with <italic>mahonia</italic> extracts (<italic>Mahonia aquifolium</italic>), in which the potential active chemical ingredient was speculated to have an anti-inflammatory mechanism [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par14">We report the first randomized, double-blind, placebo-controlled clinical trial to evaluate the pharmacological effect of <italic>Indigo naturalis</italic> as a single topical agent (topical ointment) in Chinese patients with moderate plaque-type psoriasis. Additionally, global gene expression analysis of affected skin was conducted to establish a molecular signature of moderate psoriasis (in our Chinese cohort and in&#x000a0;a predominantly White cohort [<xref ref-type="bibr" rid="CR32">32</xref>]), and used to assess the impact of <italic>Indigo naturalis</italic> treatment. Finally, major chemical components of <italic>Indigo naturalis</italic> were evaluated for anti-IL-17-induced cytokine release in cultured keratinocytes.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Clinical study</title><p id="Par15">This randomized, double-blinded, placebo-controlled study was registered with the Institutional Review Board of China Medical University Hospital, Taiwan on December 13, 2012. All patients provided written informed consent prior to enrollment. Patients were eligible to be included in the study if at baseline they were 20&#x02013;65&#x000a0;years, had a diagnosis of plaque-type psoriasis for &#x02265;6&#x000a0;months, a Physician's Global Assessment (PGA) score of 2&#x02013;3, &#x0003c;20% total body surface area (BSA) involvement, and a target plaque of &#x02265;4&#x000a0;cm<sup>2</sup>.</p><p id="Par16">Patients were excluded if they had non-plaque psoriasis, rebound/flare of chronic psoriasis, history of psoriatic arthritis, current drug-induced psoriasis, were pregnant/nursing/planning pregnancy (men and women), used biologics within 3&#x000a0;months or 5 times the half-life, received phototherapy/systemic treatment within 4&#x000a0;weeks, topicals within 2&#x000a0;weeks, any systemic immunosuppressants within 4&#x000a0;weeks, lithium/antimalarial/intramuscular gold within 4&#x000a0;weeks, tested positive for HIV/hepatitis B/C, had a&#x000a0;history of alcohol/drug abuse, clinically-significant laboratory abnormality, sensitivity to Chinese herbs/olive oil/microcrystalline wax/Vaseline, had&#x000a0;current signs/symptoms of severe, progressive, or uncontrolled medical conditions, or were participating concurrently in an investigational study. Patients were asked to maintain a daily diary to document treatment compliance and adverse events.</p></sec><sec id="Sec4"><title>Study agents</title><p id="Par17">
<italic>Indigo naturalis</italic> (Qing Dai) was extracted from the aerial part of <italic>Baphicacanthus cusia</italic> and stored as dried powder<italic>.</italic> The <italic>Indigo naturalis</italic> ointment was composed of a 1:10 mixture of <italic>Indigo naturalis</italic> powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio) (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake [Blue #2] and 45.2% Allura Red AC aluminum lake [Red #40] powders), Vaseline, microcrystalline wax, and olive oil. Across three batches of extracts, consistent indigo (2.83%) and indirubin (0.24%) concentration levels were maintained. To maintain the blind, both the <italic>Indigo naturalis</italic> and the placebo-control agents had a blue color (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). The blue dye of <italic>Indigo naturalis</italic> is not considered an active ingredient. Both study agents were manufactured at the same Good Manufacturing Practice facility (Sheng Chang Pharmaceutical Co., Ltd., Taoyuan, Taiwan). High-performance liquid chromatography was used for quality control of&#x000a0;the final product.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design. (<bold>a</bold>) Patient disposition; (<bold>b</bold>) study design; (<bold>c</bold>) study agent and placebo. The <italic>Indigo naturalis</italic> ointment used was a mixture (1:10) of <italic>Indigo naturalis</italic> powder and vehicle (Vaseline, microcrystalline wax, and olive oil [5:6:9]). Placebo preparation used was a mixture of blue dye powder (Indigo carmine aluminum lake [Blue #2] and Allura red AC aluminum lake [Red #40]) and vehicle</p></caption><graphic xlink:href="12906_2017_1947_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec5"><title>Sample size</title><p id="Par18">Sample size was calculated using the hypothesis that a decrease in&#x000a0;Psoriasis Area and Severity Index (PASI) scores at week 8 would be observed following <italic>Indigo naturalis</italic> treatment. It has been reported that a sample size of 7 placebo patients and 12 <italic>Indigo naturalis</italic> patients was needed to achieve a statistical power of 90% at 0.05 level of significance [<xref ref-type="bibr" rid="CR19">19</xref>]. Assuming a patient follow-up rate of 0.9, it was determined that at least 8 placebo patients and 16 <italic>Indigo naturalis</italic> patients would be needed to reach statistical significance.</p></sec><sec id="Sec6"><title>Study design</title><p id="Par19">A total of 24 patients with moderate psoriasis were randomized 1:2 at week 0 to placebo (<italic>n</italic>&#x000a0;=&#x000a0;8) or <italic>Indigo naturalis</italic> (<italic>n</italic>&#x000a0;=&#x000a0;16) (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Prior to week 8, one patient (placebo) discontinued due to gout. Patients were given and instructed to use the topical ointment twice daily for 8&#x000a0;weeks or until complete skin clearance was achieved, whichever occurred first. The amount of ointment used was assessed by estimating the surface area of each psoriatic lesion. To calculate the number of fingertip units (FTUs) to be used, 1 FTU&#x000a0;=&#x000a0;0.5&#x000a0;g&#x000a0;=&#x000a0;100&#x000a0;cm<sup>2</sup> of surface area. In the 4-week screening period prior to treatment, whole blood, lesional, and nonlesional biopsy samples were collected. At week 0, patients received their first treatment. Subsequent visits occurred at weeks 1, 2, 4, 6, 8, and 9. Final whole blood and lesional samples were collected at week 8 (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>).</p></sec><sec id="Sec7"><title>Study assessments</title><p id="Par20">Safety and tolerability were evaluated through week 9. Safety evaluations included adverse event assessments, physical exams, electrocardiogram measurements, and hematology and blood chemistry analyses. Tolerability was evaluated through week 9 using: PASI to measure the severity of psoriasis ranging from a score of 0 (no psoriasis) to&#x000a0;72 (very severe); BSA involvement with psoriasis; PGA scores ranging from 0 to 5: cleared (0), minimal (1), mild (2), moderate (3), marked (4), and severe (5); and Overall Target Plaque Severity Scores (OTPSS) that measures plaque severity ranging from a score of 0 (no evidence of disease) to&#x000a0;8 (very severe).</p></sec><sec id="Sec8"><title>Skin biopsy and gene expression microarray</title><p id="Par22">Two adjacent 4-mm punch biopsy specimens of lesional and nonlesional skin were obtained from each patient at week 0. A repeat biopsy was taken from the same lesional area 8 weeks after treatment with <italic>Indigo naturalis</italic> or placebo. Ribonucleic acid (RNA) was amplified using the NuGen Ovation&#x000ae; RNA Amplification System (Nugen, San Carlos, CA). The fragmented cDNA was hybridized to Affymetrix HT HG-U133&#x000a0;+&#x000a0;PM Array (Affymetrix, Santa Clara, CA).</p><p id="Par23">Microarray data were analyzed using ArrayStudio (Omicsoft, Cary, NC). Overall, 68 samples passed quality control analysis including 23 nonlesional samples and 24 lesional samples at baseline, and 21 lesional samples at week 8. Group comparisons were assessed using a general linear model (fold-change cutoff&#x000a0;=&#x000a0;1.5) followed by multiple test correction using false discovery rate&#x000a0;methodology (cutoff&#x000a0;=&#x000a0;0.05). Pathway level analysis of differentially expressed genes (DEG) was conducted using enrichment analysis in Ingenuity Pathway Analysis (<ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">http://www.ingenuity.com</ext-link>).</p></sec><sec id="Sec9"><title>Inhibition of IL-17-induced cytokine release in keratinocytes</title><p id="Par24">Normal human adult keratinocytes (Lonza) were seeded into 48-well culture plates and cultured to passage three with an approximate density of 70&#x02013;80%. Keratinocytes were stimulated with IL-17A (100&#x000a0;ng/mL) (R&#x00026;D Systems, Inc., Minneapolis, MN) and treated with varying concentrations of isatin, tryptanthrin, and indirubin (Sigma-Aldrich, St. Louis, MO), and a control compound, PD 0325901 [<xref ref-type="bibr" rid="CR33">33</xref>]. PD 0325901 is a mitogen-activated protein kinase kinase (MEK) inhibitor; a similar compound has been demonstrated to inhibit IL-17-induced cytokine release [<xref ref-type="bibr" rid="CR34">34</xref>]. Cell viability was confirmed using the PrestoBlue&#x000ae; assay (Thermo Fisher Scientific, Waltham, MA). Tryptanthrin showed no impact on cell viability at all testing concentrations. Tissue culture supernatants were analyzed for pro-inflammatory cytokines IL-6 and IL-8 using MesoScale Discovery V-plex assay (MesoScale Discovery, Rockville, MD). Data were analyzed using Graphpad Prism v5.0 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">http://www.graphpad.com</ext-link>).</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par21">Descriptive statistics such as mean, median, standard deviation, and proportion were used. No imputation of missing observations was performed. Safety was assessed by summarizing the incidence and type of adverse events through week 9. Bivariate statistical analysis such as the Chi-square test or Fisher&#x02019;s exact test for categorical variables and two-sample t test for continuous variables were employed to evaluate the differences in baseline demographic and outcomes variables between active treatment and placebo groups.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Baseline demographics and disease characteristics</title><p id="Par25">Of the 31 patients screened, 24 patients were randomized 2:1 to receive <italic>Indigo naturalis</italic> (<italic>n</italic>&#x000a0;=&#x000a0;16) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;8); 23 patients completed the study (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). All patients were Asian, and 70.8% were men (Table <xref rid="Tab1" ref-type="table">1</xref>). At baseline, the extent of BSA involvement with psoriasis was approximately 9%; the mean PASI score was approximately 10; and the mean PGA score was approximately 3 (Table <xref rid="Tab1" ref-type="table">1</xref>), consistent with moderate psoriasis [<xref ref-type="bibr" rid="CR35">35</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics and disease characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo</th><th>
<italic>Indigo naturalis</italic>
</th><th>Total</th></tr></thead><tbody><tr><td>Patients randomized, n</td><td>8</td><td>16</td><td>24</td></tr><tr><td>Men, n (%)</td><td>7 (87.5)</td><td>10 (62.5)</td><td>17 (70.8)</td></tr><tr><td colspan="4">Race, n (%)</td></tr><tr><td>&#x02003;Asian</td><td>8 (100)</td><td>16 (100)</td><td>24 (100)</td></tr><tr><td>Age, years</td><td>40.1&#x02009;&#x000b1;&#x02009;10.9</td><td>39.3&#x02009;&#x000b1;&#x02009;10.1</td><td>39.6&#x02009;&#x000b1;&#x02009;10.1</td></tr><tr><td>Weight, kg</td><td>74.1&#x02009;&#x000b1;&#x02009;16.7</td><td>73.2&#x02009;&#x000b1;&#x02009;16.0</td><td>73.5&#x02009;&#x000b1;&#x02009;15.9</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>25.2&#x02009;&#x000b1;&#x02009;4.6</td><td>25.9&#x02009;&#x000b1;&#x02009;3.9</td><td>25.7&#x02009;&#x000b1;&#x02009;4.0</td></tr><tr><td>Duration of psoriasis, years</td><td>14.9&#x02009;&#x000b1;&#x02009;12.1</td><td>13.1&#x02009;&#x000b1;&#x02009;11.1</td><td>13.7&#x02009;&#x000b1;&#x02009;11.2</td></tr><tr><td>Age at diagnosis, years</td><td>25.3&#x02009;&#x000b1;&#x02009;13.3</td><td>26.2&#x02009;&#x000b1;&#x02009;12.0</td><td>25.7&#x02009;&#x000b1;&#x02009;11.2</td></tr><tr><td>BSA involvement (%),</td><td>9.6&#x02009;&#x000b1;&#x02009;5.8</td><td>8.4&#x02009;&#x000b1;&#x02009;5.8</td><td>8.8&#x02009;&#x000b1;&#x02009;5.7</td></tr><tr><td>PASI score (0&#x02013;72)</td><td>11.1&#x02009;&#x000b1;&#x02009;3.7</td><td>10.1&#x02009;&#x000b1;&#x02009;4.3</td><td>10.4&#x02009;&#x000b1;&#x02009;4.0</td></tr><tr><td>&#x02003;&#x02265;&#x000a0;10, n (%)</td><td>4 (50.0)</td><td>8 (50.0)</td><td>12 (50.0)</td></tr><tr><td>&#x02003;&#x0003c;&#x000a0;10, n (%)</td><td>4 (50.0)</td><td>8 (50.0)</td><td>12 (50.0)</td></tr><tr><td>PGA score</td><td>3.3&#x02009;&#x000b1;&#x02009;0.5</td><td>3.0&#x02009;&#x000b1;&#x02009;0.5</td><td>3.1&#x02009;&#x000b1;&#x02009;0.5</td></tr><tr><td>OTPSS</td><td>3.8&#x02009;&#x000b1;&#x02009;0.5</td><td>3.6&#x02009;&#x000b1;&#x02009;0.5</td><td>3.6&#x02009;&#x000b1;&#x02009;0.5</td></tr></tbody></table><table-wrap-foot><p>Values are mean&#x000a0;&#x000b1;&#x000a0;SD, unless otherwise indicated</p><p>
<italic>BSA</italic> body surface area, <italic>OTPSS</italic> Overall Target Plaque Severity Score, <italic>PASI</italic> Psoriasis Area and Severity Index, <italic>PGA</italic> Physician's Global Assessment, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Efficacy</title><p id="Par26">PASI scores were measured at baseline and each visit through week 9. Baseline PASI scores were similar between the two groups (Table <xref rid="Tab1" ref-type="table">1</xref>). As early as week 2, <italic>Indigo naturalis</italic>-treated patients showed a statistically significant difference in mean PASI score compared with placebo-treated patients (<italic>p</italic>&#x000a0;=&#x000a0;0.02; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). At week 8, the time of the last <italic>Indigo naturalis</italic> treatment, the mean PASI score of <italic>Indigo naturalis</italic> patients was 2.64&#x000a0;&#x000b1;&#x000a0;1.5 representing a significant improvement from baseline (<italic>p</italic>&#x000a0;=&#x000a0;0.01) and a significant difference compared with placebo patients (8.30&#x000a0;&#x000b1;&#x000a0;4.0; <italic>p</italic>&#x000a0;=&#x000a0;0.01; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Moreover, 56.3% of <italic>Indigo naturalis</italic> patients achieved at least a 75% improvement in PASI (PASI 75 response) at week 8 compared with none of the placebo patients (0/7; 0.0%; <italic>p</italic>&#x000a0;=&#x000a0;0.02; Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). Consistent with PASI results, baseline PGA scores were similar between the two groups; however, a significant difference in mean PGA score was observed between <italic>Indigo naturalis</italic> patients (1.31&#x000a0;&#x000b1;&#x000a0;0.6) and placebo patients at week 8 (2.29&#x000a0;&#x000b1;&#x000a0;0.8; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.003; Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Similarly, a significant difference in mean was observed between <italic>Indigo naturalis</italic> (1.31&#x000a0;&#x000b1;&#x000a0;0.9) and placebo patients (2.86&#x000a0;&#x000b1;&#x000a0;1.5) at week 8 (<italic>p</italic>&#x000a0;=&#x000a0;0.003; Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). An example of a skin lesion pre- and post-<italic>Indigo naturalis</italic> treatment is shown in Fig. <xref rid="Fig2" ref-type="fig">2e</xref>. At week 9 however, the mean PASI score for the <italic>Indigo naturalis</italic> patients was 3.74&#x000a0;&#x000b1;&#x000a0;2.3, indicating diminished efficacy following termination of treatment.<fig id="Fig2"><label>Fig. 2</label><caption><p>Efficacy assessments. (<bold>a</bold>) Mean PASI scores; (<bold>b</bold>) proportion of placebo- and <italic>Indigo naturalis</italic>-treated patients achieving a PASI 75 response (PASI 75 responders); (<bold>c</bold>) mean PGA scores; (<bold>d</bold>) and mean OTPSS in placebo- and <italic>Indigo naturalis</italic>-treated patients by study visit; (<bold>e</bold>) photo of a patient prior to <italic>Indigo naturalis</italic> treatment at week 0 (baseline) (<italic>left panel</italic>) and at week 8 following <italic>Indigo naturalis</italic> treatment (right panel). <sup>*</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and <sup>**</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.005 vs. placebo. OTPSS, Overall Target Plaque Severity Score; PASI, Psoriasis Area and Severity Index; PGA, Physician's Global Assessmen t; SD, standard deviation</p></caption><graphic xlink:href="12906_2017_1947_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec14"><title>Safety</title><p id="Par27">
<italic>Indigo naturalis</italic> was well-tolerated. With an average duration of follow-up of approximately 9&#x000a0;weeks, the proportion of patients with at least one adverse event was comparable between treatment groups (placebo: 50.0%; <italic>Indigo naturalis</italic>: 44.0%; Table <xref rid="Tab2" ref-type="table">2</xref>). The most common adverse event in the <italic>Indigo naturalis</italic> group was pruritus (25.0%), followed by rash and nasopharyngitis (each 12.5%) and single events of pruritus, gout, allergies, and pyrexia were reported in the placebo group (all 12.5%). One placebo-treated patient discontinued treatment prior to study completion (at week 3) due to an adverse event of gout (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patient safety data through week 9</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo</th><th>
<italic>Indigo naturalis</italic>
</th></tr></thead><tbody><tr><td>Patients treated, n</td><td>8</td><td>16</td></tr><tr><td>Patients with &#x0003e;1 adverse event, n (%)</td><td>4 (50.0)</td><td>7 (44.0)</td></tr><tr><td>Average duration of follow-up (weeks)</td><td>9.14</td><td>9.13</td></tr><tr><td>Average exposure (weeks)</td><td>8.16</td><td>8.13</td></tr><tr><td colspan="3">Common adverse events, n (%)</td></tr><tr><td>&#x02003;Pruritus</td><td>1 (12.5)</td><td>4 (25.0)</td></tr><tr><td>&#x02003;Rash</td><td>0 (0.0)</td><td>2 (12.5)</td></tr><tr><td>&#x02003;Nasopharyngitis</td><td>0 (0.0)</td><td>2 (12.5)</td></tr><tr><td>&#x02003;Abdominal distension</td><td>0 (0.0)</td><td>1 (6.3)</td></tr><tr><td>&#x02003;Constipation</td><td>0 (0.0)</td><td>1 (6.3)</td></tr><tr><td>&#x02003;Cough</td><td>0 (0.0)</td><td>1 (6.3)</td></tr><tr><td>&#x02003;Dizziness</td><td>0 (0.0)</td><td>1 (6.3)</td></tr><tr><td>&#x02003;Oropharyngeal pain</td><td>0 (0.0)</td><td>1 (6.3)</td></tr><tr><td>&#x02003;Gout</td><td>1 (12.5)</td><td>0 (0.0)</td></tr><tr><td>&#x02003;Allergies</td><td>1 (12.5)</td><td>0 (0.0)</td></tr><tr><td>&#x02003;Pyrexia</td><td>1 (12.5)</td><td>0 (0.0)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec15"><title>Gene expression signature of moderate psoriasis</title><p id="Par28">To gain a comprehensive understanding of the molecular characteristics of moderate psoriasis represented by this cohort, a global gene expression profile was generated from skin biopsies. Baseline lesional skin samples were compared with nonlesional samples from the same patients (<italic>n</italic>&#x000a0;=&#x000a0;24). A total of 6845 probe sets with significant modulation (3384 up and 3461 down) were identified. The corresponding 4320 DEG define a disease signature of moderate psoriasis. A hierarchical clustering analysis showed distinct expression patterns of these genes in psoriatic lesions compared with nonlesional skin (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). To gain functional insight to the disease signature, a pathway enrichment analysis was conducted that resulted in 193 enriched pathways (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>). The top 15 pathways (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>) included the &#x0201c;Role of IL-17A in psoriasis,&#x0201d; indicating that the IL-17 pathway is a key component of moderate psoriasis.<fig id="Fig3"><label>Fig. 3</label><caption><p>Moderate psoriasis signature. (<bold>a</bold>) Hierarchical clustering diagram of a moderate psoriasis signature generated from biopsies taken from lesional skin (LS; <italic>blue bar</italic>) and nonlesional skin (NS; <italic>green bar</italic> at the bottom) of the same patients at baseline; genes are represented as rows and samples as columns. Upregulated genes are shown in <italic>yellow</italic> and downregulated in <italic>blue</italic>; (<bold>b</bold>) enrichment of ingenuity pathways by moderate psoriasis gene signature. The stacked bar chart displays the number of up-regulated (<italic>red</italic>) and down-regulated (<italic>green</italic>) genes&#x000a0;in each Ingenuity Canonical Pathway. The pathways are ranked by the <italic>p</italic>-value of a Fisher exact test from top to bottom (<italic>orange line</italic>; <italic>p</italic>-value listed in Additional file S1)</p></caption><graphic xlink:href="12906_2017_1947_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par29">Because our study population was composed entirely of Asian patients, we performed a comparison to another psoriasis population [<xref ref-type="bibr" rid="CR32">32</xref>] that was predominantly White. That study population [<xref ref-type="bibr" rid="CR32">32</xref>] consisted of a similar sample size (<italic>n</italic>&#x000a0;=&#x000a0;25 vs. <italic>n</italic>&#x000a0;=&#x000a0;24), with slightly higher baseline PASI scores (average 14.1 vs. 10.1), and comparable baseline PGA scores (average 2.7 vs. 3.1). The same statistical approach used for comparing nonlesional samples to lesional samples at baseline resulted in 4585 DEG. The two signatures shared approximately 62% of genes that were modulated in the same direction. Pathway enrichment analyses showed that 78% of the underlying pathways were shared (see Additional files <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>). &#x0201c;Role of IL-17A in psoriasis&#x0201d; ranked high in both signatures, supporting its role in both populations studied.</p></sec><sec id="Sec16"><title>Gene expression signature of <italic>Indigo naturalis</italic> treatment</title><p id="Par30">To investigate the pharmacological impact of <italic>Indigo naturalis</italic> treatment, gene expression patterns of post-treatment lesional skin were compared to pre-treatment lesional skin in the scope of the disease signature. By hierarchical clustering, 8/14 <italic>Indigo naturalis</italic>-treated week-8 samples were clustered together with baseline nonlesional samples, indicative of a return toward normal gene expression patterns, compared with only one placebo-treated sample (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). Five <italic>Indigo naturalis</italic> and two placebo-treated samples showed a mixed pattern between baseline lesional and nonlesional samples, indicating heterogeneity of the treatment effects.<fig id="Fig4"><label>Fig. 4</label><caption><p>
<italic>Indigo naturalis</italic> treatment signature. (<bold>a</bold>) Hierarchical clustering diagram of baseline and post-<italic>Indigo naturalis</italic> treatment (week 8) samples of the entire study cohort; genes are represented as rows and samples as columns. Upregulated genes are shown in <italic>yellow</italic> and downregulated in <italic>blue</italic>. Samples from four different groups are denoted as follows: baseline lesional (BL_LS; <italic>blue</italic>), baseline nonlesional (BL_NL; <italic>green</italic>), week-8 <italic>Indigo naturalis</italic>-treated lesional (W8_LS_IND; <italic>purple</italic>), and week-8 placebo-treated (W8_LS_PLB; <italic>yellow</italic>); (<bold>b</bold>) a Venn diagram comparing moderate psoriasis gene signature (<italic>dark blue</italic> circle on the left) and <italic>Indigo naturalis</italic> treatment signature (<italic>light blue</italic> circle on the right); (<bold>c</bold>) enrichment of Ingenuity pathways by <italic>Indigo naturalis</italic> treatment gene signature. The stacked bar chart displays the number of up-regulated (<italic>red</italic>) and down-regulated (<italic>green</italic>) in each Ingenuity Canonical Pathway. The pathways are ranked by the <italic>p</italic>-value of a Fisher exact test from top to bottom (orange line; <italic>p</italic>-value listed in Additional file <xref rid="MOESM3" ref-type="media">3</xref>); (<bold>d</bold>) the &#x0201c;Role of IL-17A in psoriasis&#x0201d; pathway overlaid with the gene expression pattern and each circle represents one gene. Differential expression between lesional and nonlesional sample at baseline is shown in left-half of each circle, and differential expression between week 8 and baseline samples is shown in right- half of circles. <italic>Yellow</italic>&#x000a0;=&#x000a0;up-regulated, <italic>blue</italic>&#x000a0;=&#x000a0;down-regulated, IL = interleukin,&#x000a0;RA, receptor A, RC, receptor C</p></caption><graphic xlink:href="12906_2017_1947_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par31">A gene signature of <italic>Indigo naturalis</italic> treatment was generated by comparing week-8 lesional skin to the matched baseline samples from nine patients who achieved PASI 75 responses. The signature consisted of 5324 probe sets that corresponded to 3427 DEG (data not shown). When compared with the disease signature, 69% of genes were in common, but regulated in the opposite direction, indicating that a majority of the disease signature genes were impacted by the treatment (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Enrichment analysis for this treatment signature also supports an impact on the majority of disease pathways (4 of 5 top pathways were identical to that of the disease signature, but in the opposite direction of gene regulation) (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>; see Additional file <xref rid="MOESM3" ref-type="media">3</xref>). The pathway &#x0201c;Role of IL-17A in psoriasis&#x0201d; ranked even higher in this analysis than in the disease signature, and all pathway genes were reversely regulated (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). For example, IL-17A expression was decreased by 4.8-fold following <italic>Indigo naturalis</italic> treatment (<italic>p</italic>&#x000a0;=&#x000a0;4.6 E-11) versus a non-significant 1.7-fold decrease with placebo treatment (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Together, these data provide evidence that expression of IL-17A and its pathway genes was upregulated in psoriatic lesions of our study patients and down-regulated after <italic>Indigo naturalis</italic> treatment.<fig id="Fig5"><label>Fig. 5</label><caption><p>
<italic>Indigo naturalis</italic>&#x02019; impact on the IL-17 pathway. (<bold>a</bold>) Down-regulation of interleukin (IL)-17A mRNA in the lesional skin (LS). <italic>Indigo naturalis</italic>-treated samples (<italic>blue filled-circle</italic>) are the left columns (week 0 [WK 0]: <italic>n</italic>&#x000a0;=&#x000a0;16; week 8 [WK 8]: <italic>n</italic>&#x000a0;=&#x000a0;14); placebo-treated samples (<italic>green triangles</italic>) are the middle two columns (WK 0: <italic>n</italic>&#x000a0;=&#x000a0;8; WK 8: <italic>n</italic>&#x000a0;=&#x000a0;7), and baseline nonlesional (NL) samples (gray square) are the right column (<italic>n</italic>&#x000a0;=&#x000a0;23); (<bold>b</bold>) inhibition of IL-17-induced IL-6 secretion in cultured human keratinocytes. 100&#x000a0;mg/mL of IL-17 is present in all samples except media alone (first column). Compounds are tested in the following order: PD 0325901 1&#x000a0;&#x003bc;g (<italic>n</italic>&#x000a0;=&#x000a0;2), 10&#x000a0;&#x003bc;g (<italic>n</italic>&#x000a0;=&#x000a0;2); Tryptanthrin 0.3&#x000a0;&#x003bc;g (<italic>n</italic>&#x000a0;=&#x000a0;7), 2.5&#x000a0;&#x003bc;g (<italic>n</italic>&#x000a0;=&#x000a0;7) and 10&#x000a0;&#x003bc;g (<italic>n</italic>&#x000a0;=&#x000a0;7). <sup>*</sup>T-test <italic>p</italic>-value &#x02264;0.05; (<bold>c</bold>) inhibition of IL-17-induced IL-8 secretion in cultured human keratinocytes. 100&#x000a0;mg/mL of IL-17 is present in all samples except media alone (first column). IL, interleukin; mRNA, messenger RNA; SEM, standard error of mean</p></caption><graphic xlink:href="12906_2017_1947_Fig5_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec17"><title>Inhibition of IL-17-induced cytokine release by chemical compounds in <italic>Indigo naturalis</italic></title><p id="Par32">To further understand the mechanism of action, the three major chemical components of <italic>Indigo naturalis</italic>&#x02014; isatin, indirubin, and tryptanthrin&#x02014; were evaluated for IL-17 inhibition activity using an IL-17-induced cytokine release assay. Cultured human keratinocytes were stimulated with IL-17A (100&#x000a0;ng/mL), which resulted in a 4.5- and 5.5-fold increase in secretion of the pro-inflammatory cytokines IL-6 and IL-8, respectively. This elevation in production of these cytokines was inhibited by the MEK inhibitor PD 0325901 (Fig. <xref rid="Fig5" ref-type="fig">5b &#x00026; c</xref>), but was not affected by the presence of isatin and indirubin (data not shown). On the contrary, tryptanthrin showed moderate, but significant inhibition, reducing IL-6 secretion by nearly half at the highest concentration tested (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). More moderate reduction of IL-17-stimulated IL-8 secretion was also observed (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>).</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par33">
<italic>Indigo naturalis</italic> is a TCM long recognized as a therapy for several inflammatory conditions [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Previous clinical studies have shown that monotherapy as a topical agent can be an effective treatment for mild-to-moderate psoriasis [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]; however, interpretation of these studies is limited due to the lack of proper placebo controls. There also remains little understanding of the mechanism of action, although there is anecdotal evidence attributed to the anti-proliferation activity of indirubin [<xref ref-type="bibr" rid="CR27">27</xref>]. Our study was designed to address these critical questions at the both the clinical and molecular level.</p><p id="Par34">Previous clinical studies have included intra-patient placebo controls: placebo was applied to one side of the body, and <italic>Indigo naturalis</italic> to the other side of the same patient. Therefore, it was not administered in a truly blinded manner, and there was the possibility of exposure of active agent to the contra-lateral, placebo-exposed side via potential percutaneous absorption [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. To avoid bias, our study was designed as a double-blinded, placebo-control trial in which each patient was assigned to either active agent or placebo. Furthermore, the placebo was prepared using a blue color to match the active agent in appearance and to maintain the study blinding to prevent any possible bias.</p><p id="Par35">We generated, for the first time, a comprehensive profile of molecular changes associated with moderate psoriasis and with the treatment effect of <italic>Indigo naturalis</italic> in skin. As in more severe disease, deregulation of IL-17 expression was observed in the more moderate population in this study. We presented evidence that topical <italic>Indigo naturalis</italic> significantly down-regulated the IL-17 pathway in affected skin, similar to other therapies that successfully target this pathway [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Moreover, we showed that one of the chemical components in <italic>Indigo naturalis</italic>, tryptanthrin, possesses moderate anti-IL-17 activity. To our knowledge, this is the first report that associates <italic>Indigo naturalis</italic>, in particular one of its chemical ingredients, tryptanthrin, with anti-IL-17 activity. Although an earlier study found that indirubin derivatives can inhibit STAT3 [<xref ref-type="bibr" rid="CR41">41</xref>], which was shown to be a required transcription factor for Th17 differentiation [<xref ref-type="bibr" rid="CR42">42</xref>], the link between indirubin-STAT3 and IL-17 has not been directly proven.</p><p id="Par36">Although there has been a great deal of interest in understanding the pharmacologic mechanism of TCMs, limited progress has been made. One challenge is identifying the active components within TCM, as there may be numerous chemical components in a single TCM. Here, we have employed a different approach by first generating a treatment molecular signature and then identifying the specific pathways that are affected by TCM treatment, resulting in a hypothesis (IL-17 inhibition) that could be tested using purer chemical components.</p><p id="Par37">We have made an effort to compare the disease signatures generated from our study population to a similar study [<xref ref-type="bibr" rid="CR32">32</xref>] with a predominantly White population. The two signatures are mostly overlapping, indicating that the underlying driver of the disease may be the same in both psoriasis populations and suggesting that <italic>Indigo naturalis</italic> should be effective in broader populations of psoriasis patients.</p><p id="Par38">There were a few limitations in this study, including small sample size and no systemic marker measurement. The latter limited the ability to address the reasons behind the short benefit duration of topical <italic>Indigo naturalis</italic> treatment. It is unknown whether this could be due to the lack of deeper skin penetration, leading to lower systemic exposure, or a relatively short half-life of the effective chemical ingredients. Future studies with a larger sample size and additional markers, such as serum tryptanthrin and IL-17 levels, would be more informative<bold>.</bold>
</p></sec><sec id="Sec19"><title>Conclusion</title><p id="Par39">In summary, this experimental medicine study in patients with moderate psoriasis identified IL-17 as a key pathway that can be modulated by treatment with <italic>Indigo naturalis</italic>. This study exemplified a novel approach to understanding the mechanism of action of a TCM, which may be applied to understanding the therapeutic effect of other forms of TCMs.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12906_2017_1947_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>Enrichment of ingenuity pathways by moderate psoriasis gene signature from our study population. (DOCX 22&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12906_2017_1947_MOESM2_ESM.docx"><label>Additional file 2:</label><caption><p>Enrichment of ingenuity pathways by gene signature from a predominately White psoriasis population [<xref ref-type="bibr" rid="CR27">27</xref>]. (DOCX 18&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12906_2017_1947_MOESM3_ESM.docx"><label>Additional file 3:</label><caption><p>Enrichment of ingenuity pathways by gene signature of <italic>Indigo naturalis</italic> treatment of moderate psoriasis from our study population. (DOCX 23&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BSA</term><def><p id="Par6">Body surface area</p></def></def-item><def-item><term>DEG</term><def><p>differentially expressed genes</p></def></def-item><def-item><term>FTU</term><def><p>fingertip units</p></def></def-item><def-item><term>IL</term><def><p id="Par7">Interleukin</p></def></def-item><def-item><term>MEK</term><def><p>mitogen-activated protein kinase kinase</p></def></def-item><def-item><term>OTPSS</term><def><p id="Par8">Overall Target Plaque Severity Score</p></def></def-item><def-item><term>PASI 75</term><def><p id="Par9">75% improvement in PASI score from baseline</p></def></def-item><def-item><term>PASI</term><def><p>Psoriasis Area and Severity Index</p></def></def-item><def-item><term>PGA</term><def><p id="Par10">Physician&#x02019;s Global Assessment</p></def></def-item><def-item><term>RNA</term><def><p>ribonucleic acid</p></def></def-item><def-item><term>STAT-3</term><def><p>signal transducer and activator of transcription-3</p></def></def-item><def-item><term>TCM</term><def><p id="Par11">Traditional Chinese Medicine</p></def></def-item><def-item><term>Th</term><def><p>T helper</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p>tumor necrosis factor-alpha</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12906-017-1947-1) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Kristin Ruley Sharples, PhD, of Janssen Scientific Affairs, LLC (Spring House, PA), for her writing and editorial support in the preparation of this manuscript; Mary Whitman, PhD, of Janssen Scientific Affairs, LLC (Spring House, PA), for her critical input; and Bart Frederick of Janssen Research &#x00026; Development, LLC (Spring House, PA), for providing technical support for the patient photographs.</p><sec id="FPar1"><title>Funding</title><p id="Par40">This study was funded by Janssen Research &#x00026; Development, LLC and was partially supported by the grants from Ministry of Science and Technology and China Medical University under the Aim for Top University Plan of the Ministry of Education, Taiwan.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par41">The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>H-MC was the Principal Investigator of the clinical study, provided and characterized patient samples, conducted the clinical study, wrote the Clinical Study Report, and was involved in the study concept development, study design, protocol synopsis and manuscript development; Y-CW was the Principal Investigator of this clinical project and involved in the study design, data analysis, and manuscript development; QW was involved in the study design, protocol synopsis development, study coordination, data analysis, and manuscript development; MS was involved in the study design, protocol synopsis development, study coordination (clinical), data analysis, and manuscript development; JW was involved in the study concept development, study coordination, and manuscript development; DC was involved in the study design, protocol synopsis development, analysis of the data, and manuscript development; KL was involved in the study design, protocol synopsis development, and manuscript development; EW was involved in the in vitro keratinocyte cytokine release assay development and manuscript development; S-TK participated in the study design, protocol synopsis development, and data interpretation; T-CL was the chief biostatistician and was responsible for the data management and analysis, and manuscript development; FL was the Janssen-responsible officer for this study, involved in the study concept development, interpretation of data, and manuscript development; KH was involved in the mRNA isolation and manuscript development; CB was involved in the manuscript development; CCH was involved in the study concept development, study design, protocol synopsis development, data analysis, manuscript development, and communication with all co-authors. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par42">This study was approved by the Institutional Review Board of China Medical University Hospital, Taiwan, and conducted at this institute. The protocol followed Declaration of Helsinki and detailed information can be found at the <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">Clinicaltrials.gov</ext-link> website (NCT01901705). All patients provided written informed consent prior to any study-related procedures, and agreed to return for follow-up visits and provide all required biopsies.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par43">Patients provided written consent for their photographs to be used in this study and publication.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par44">Q. Wang, M. Song, D. Chen, K. Li, E. Wadman, F. Leon, K. Hayden, C. Brodmerkel, and C. C. Huang are all employees of Janssen Research &#x00026; Development, LLC, a subsidiary of Johnson &#x00026; Johnson, and Q. Wang, M. Song, D. Chen, K. Li, F. Leon, C. Brodmerkel, and C. C. Huang own stock in Johnson &#x00026; Johnson.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par45">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;n</surname><given-names>MP</given-names></name><name><surname>Boehncke</surname><given-names>WH</given-names></name></person-group><article-title>Psoriasis</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1899</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.1056/NEJMra041320</pub-id><pub-id pub-id-type="pmid">15872205</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence of psoriasis in China: an epidemiological survey in six provinces</article-title><source>Chin J Derm Venereol</source><year>2010</year><volume>24</volume><fpage>598</fpage><lpage>601</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H-T</given-names></name><name><surname>Lin</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>YT</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Liang</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients</article-title><source>J Rheumatol</source><year>2008</year><volume>35</volume><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">18381784</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Te-Shao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>The genetic epidemiology of psoriasis vulgaris in Chinese Han</article-title><source>Int J Dermatol</source><year>2002</year><volume>41</volume><fpage>663</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1046/j.1365-4362.2002.01596.x</pub-id><pub-id pub-id-type="pmid">12390189</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiricozzi</surname><given-names>A</given-names></name><name><surname>Guttman-Yassky</surname><given-names>E</given-names></name><name><surname>Su&#x000e1;rez-Fari&#x000f1;as</surname><given-names>M</given-names></name><name><surname>Nograles</surname><given-names>KE</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Cardinale</surname><given-names>I</given-names></name><etal/></person-group><article-title>Integrative responses to IL-17 and TNF-&#x003b1; in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/jid.2010.340</pub-id><pub-id pub-id-type="pmid">21085185</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>CL</given-names></name><name><surname>Kimball</surname><given-names>AB</given-names></name><name><surname>Papp</surname><given-names>KA</given-names></name><name><surname>Yeilding</surname><given-names>N</given-names></name><name><surname>Guzzo</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1665</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60725-4</pub-id><pub-id pub-id-type="pmid">18486739</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>KA</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Szapary</surname><given-names>P</given-names></name><name><surname>Yeilding</surname><given-names>N</given-names></name><etal/></person-group><article-title>PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60726-6</pub-id><pub-id pub-id-type="pmid">18486740</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofen</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Matheson</surname><given-names>RT</given-names></name><name><surname>Leonardi</surname><given-names>CL</given-names></name><name><surname>Calderon</surname><given-names>C</given-names></name><name><surname>Brodmerkel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Guselkumab (an IL-23&#x02013;specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis</article-title><source>J Allergy Clin Immunol</source><year>2014</year><volume>133</volume><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.01.025</pub-id><pub-id pub-id-type="pmid">24679469</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Zaba LC, Su&#x000e1;rez-Fari&#x000f1;as M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.J Allergy Clin Immunol 2009;124:1022&#x02013;10.e1&#x02013;395.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>Fretzin</surname><given-names>S</given-names></name><name><surname>Su&#x000e1;rez-Fari&#x000f1;as</surname><given-names>M</given-names></name><name><surname>Haslett</surname><given-names>PA</given-names></name><name><surname>Phipps</surname><given-names>KM</given-names></name><name><surname>Cameron</surname><given-names>GS</given-names></name><etal/></person-group><article-title>IL-17A is essential for cell activation and inflammatory gene circuits in psoriasis</article-title><source>J Allergy Clin Immunol</source><year>2012</year><volume>130</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.04.024</pub-id><pub-id pub-id-type="pmid">22677045</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balato</surname><given-names>A</given-names></name><name><surname>Schiattarella</surname><given-names>M</given-names></name><name><surname>Di Caprio</surname><given-names>R</given-names></name><name><surname>Lembo</surname><given-names>S</given-names></name><name><surname>Mattii</surname><given-names>M</given-names></name><name><surname>Balato</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway</article-title><source>J Eur Acad Dermatol Venereol</source><year>2014</year><volume>28</volume><fpage>1016</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1111/jdv.12240</pub-id><pub-id pub-id-type="pmid">24033358</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>CB</given-names></name><name><surname>Rand</surname><given-names>H</given-names></name><name><surname>Bigler</surname><given-names>J</given-names></name><name><surname>Kerkof</surname><given-names>K</given-names></name><name><surname>Timour</surname><given-names>M</given-names></name><name><surname>Bautista</surname><given-names>E</given-names></name><etal/></person-group><article-title>Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti&#x02013;IL-17 receptor monoclonal antibody</article-title><source>J Immunol</source><year>2014</year><volume>192</volume><fpage>3828</fpage><lpage>3836</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301737</pub-id><pub-id pub-id-type="pmid">24646743</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>AR</given-names></name><name><surname>Mason</surname><given-names>JM</given-names></name><name><surname>Cork</surname><given-names>MJ</given-names></name><name><surname>Hancock</surname><given-names>H</given-names></name><name><surname>Dooley</surname><given-names>G</given-names></name></person-group><article-title>Topical treatments for chronic plaque psoriasis of the scalp: a systematic review</article-title><source>Br J Dermatol</source><year>2013</year><volume>169</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1111/bjd.12393</pub-id><pub-id pub-id-type="pmid">23796133</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Arain</surname><given-names>S</given-names></name></person-group><article-title>Traditional Chinese medicine for the treatment of dermatologic disorders</article-title><source>Arch Dermatol</source><year>1998</year><volume>134</volume><fpage>1388</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1001/archderm.134.11.1388</pub-id><pub-id pub-id-type="pmid">9828872</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>TW</given-names></name></person-group><article-title>Use of common Chinese herbs in the treatment of psoriasis</article-title><source>Clin Exp Dermatol</source><year>2003</year><volume>28</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2230.2003.01322.x</pub-id><pub-id pub-id-type="pmid">12950329</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>WP</given-names></name><name><surname>Che</surname><given-names>CT</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>ZX</given-names></name></person-group><article-title>Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells</article-title><source>J Ethnopharmacol</source><year>2006</year><volume>108</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2006.04.023</pub-id><pub-id pub-id-type="pmid">16730935</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Wong</surname><given-names>WR</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Tsay</surname><given-names>PK</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><etal/></person-group><article-title>The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis</article-title><source>Dermatology</source><year>2007</year><volume>214</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1159/000098576</pub-id><pub-id pub-id-type="pmid">17341866</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Wong</surname><given-names>WR</given-names></name><name><surname>Su Pang</surname><given-names>JH</given-names></name></person-group><article-title>Successful treatment of recalcitrant psoriasis with indigo naturalis ointment</article-title><source>Clin Exp Dermatol</source><year>2007</year><volume>32</volume><fpage>99</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2230.2007.02462.x</pub-id><pub-id pub-id-type="pmid">17305912</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Wong</surname><given-names>WR</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Pang</surname><given-names>JH</given-names></name></person-group><article-title>Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis</article-title><source>Arch Dermatol</source><year>2008</year><volume>144</volume><fpage>1457</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1001/archderm.144.11.1457</pub-id><pub-id pub-id-type="pmid">19015420</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Leu</surname><given-names>YL</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Wang</surname><given-names>CT</given-names></name><name><surname>Pang</surname><given-names>JH</given-names></name></person-group><article-title>Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component</article-title><source>J Dermatol Sci</source><year>2009</year><volume>54</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2009.02.007</pub-id><pub-id pub-id-type="pmid">19303259</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Lin YK, Leu YL, Huang TH, Wu YH, Chung PJ, Su Pang JH, et al. Anti-inflammatory effects of the extract of indigo naturalis in human neutrophils. J Ethnopharmacol. 2009;25:51&#x02013;8.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Lin YK, Leu YL, Huang TH, Wu YH, Chung PJ, Su Pang JH, et al. Comparison of refined and crude indigo naturalis ointment in treating psoriasis: randomized, observer-blind, controlled, intrapatient trial. Arch Dermatol. 2012;148:397&#x02013;400.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ports</surname><given-names>WC</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Lan</surname><given-names>S</given-names></name><name><surname>Lamba</surname><given-names>M</given-names></name><name><surname>Bolduc</surname><given-names>C</given-names></name><name><surname>Bissonnette</surname><given-names>R</given-names></name><etal/></person-group><article-title>Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design</article-title><source>J Drugs Dermatol</source><year>2015</year><volume>14</volume><fpage>777</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">26267721</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoessel</surname><given-names>R</given-names></name><name><surname>Leclerc</surname><given-names>S</given-names></name><name><surname>Endicott</surname><given-names>JA</given-names></name><name><surname>Nobel</surname><given-names>ME</given-names></name><name><surname>Lawrie</surname><given-names>A</given-names></name><name><surname>Tunnah</surname><given-names>P</given-names></name><name><surname>Leost</surname><given-names>M</given-names></name><etal/></person-group><article-title>Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases</article-title><source>Nature Cell Biol</source><year>1999</year><volume>1</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/9035</pub-id><pub-id pub-id-type="pmid">10559866</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leclerc</surname><given-names>S</given-names></name><name><surname>Garnier</surname><given-names>M</given-names></name><name><surname>Hoessel</surname><given-names>R</given-names></name><name><surname>Marko</surname><given-names>D</given-names></name><name><surname>Bibb</surname><given-names>JA</given-names></name><name><surname>Snyder</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Indirubins inhibit glycogen synthase kinase-3 &#x003b2; and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002466200</pub-id><pub-id pub-id-type="pmid">11013232</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Schwaiberger AV, Heiss EH, Cabaravdic M, Oberan T, Zaujec J, Schachner D, et al. Indirubin-3&#x02032;-monoxime blocks vascular smooth muscle cell proliferation by inhibition of signal transducer and activator of transcription 3 signaling and reduces neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2010;30:2475&#x02013;81.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>WL</given-names></name><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Tsai</surname><given-names>CN</given-names></name><name><surname>Wang</surname><given-names>TM</given-names></name><name><surname>Chen</surname><given-names>TY</given-names></name><name><surname>Pang</surname><given-names>JH</given-names></name></person-group><article-title>Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes</article-title><source>J Dermatol Sci</source><year>2012</year><volume>67</volume><fpage>140</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2012.05.008</pub-id><pub-id pub-id-type="pmid">22721997</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>Y</given-names></name><name><surname>Kunikata</surname><given-names>T</given-names></name><name><surname>Aga</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Ushio</surname><given-names>S</given-names></name><name><surname>Iwaki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tryptanthrin inhibits interferon-&#x003b3; production by Peyer's patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin</article-title><source>Biol Pharm Bull</source><year>2003</year><volume>26</volume><fpage>365</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1248/bpb.26.365</pub-id><pub-id pub-id-type="pmid">12612449</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Ushio</surname><given-names>S</given-names></name><name><surname>Iwaki</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Kurimoto</surname><given-names>M</given-names></name></person-group><article-title>Tryptanthrin inhibits nitric oxide and prostaglandin E<sub>2</sub> synthesis by murine macrophages</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>407</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(00)00674-9</pub-id><pub-id pub-id-type="pmid">11050308</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>J</given-names></name><name><surname>W&#x000f6;lfle</surname><given-names>U</given-names></name><name><surname>Weckesser</surname><given-names>S</given-names></name><name><surname>Schempp</surname><given-names>C</given-names></name></person-group><article-title>Which plant for which skin disease? Part 1: atopic dermatitis, psoriasis, acne, condyloma and herpes simplex</article-title><source>J Dtsch Dermatol Ges</source><year>2010</year><volume>8</volume><fpage>788</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">20707875</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>S</given-names></name><name><surname>Donsky</surname><given-names>H</given-names></name><name><surname>Gulliver</surname><given-names>W</given-names></name><name><surname>Hamilton</surname><given-names>D</given-names></name><name><surname>Nobel</surname><given-names>S</given-names></name><name><surname>Norman</surname><given-names>R</given-names></name></person-group><article-title>Treatment of mild to moderate psoriasis with Relieva, a Mahonia Aquifolium extract&#x02014;a double-blind, placebo-controlled study</article-title><source>Am J Ther</source><year>2006</year><volume>13</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1097/00045391-200603000-00007</pub-id><pub-id pub-id-type="pmid">16645428</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132:2466&#x02013;9.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>SD</given-names></name><name><surname>Bridges</surname><given-names>AJ</given-names></name><name><surname>Dudley</surname><given-names>DT</given-names></name><name><surname>Saltiel</surname><given-names>AR</given-names></name><name><surname>Fergus</surname><given-names>JH</given-names></name><name><surname>Flamme</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901</article-title><source>Bioorg Med Chem Lett</source><year>2008</year><volume>18</volume><fpage>6501</fpage><lpage>6504</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2008.10.054</pub-id><pub-id pub-id-type="pmid">18952427</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laan</surname><given-names>M</given-names></name><name><surname>L&#x000f6;tvall</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>A</given-names></name></person-group><article-title>IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases</article-title><source>Br J Pharmacol</source><year>2001</year><volume>133</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704063</pub-id><pub-id pub-id-type="pmid">11325811</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Ellis</surname><given-names>CN</given-names></name></person-group><article-title>Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment and lattice system Physician's global assessment</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2004.04.012</pub-id><pub-id pub-id-type="pmid">15389191</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Choi</surname><given-names>YY</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Cho</surname><given-names>IH</given-names></name><name><surname>Nam</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>WM</given-names></name></person-group><article-title>Indirubin, a purple 3, 2-bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model</article-title><source>J Ethnopharmacol</source><year>2013</year><volume>145</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.10.055</pub-id><pub-id pub-id-type="pmid">23149289</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>HT</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>DD</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Tsang</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice</article-title><source>Chin Med</source><year>2015</year><volume>10</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13020-015-0061-x</pub-id><pub-id pub-id-type="pmid">26464580</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>KA</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Sigurgeirsson</surname><given-names>B</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>DR</given-names></name><name><surname>Konno</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study</article-title><source>Br J Dermatol</source><year>2013</year><volume>168</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1111/bjd.12110</pub-id><pub-id pub-id-type="pmid">23106107</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>K</given-names></name><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Ortonne</surname><given-names>JP</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>Kricorian</surname><given-names>G</given-names></name><etal/></person-group><article-title>Brodalumab, an anti&#x02013;interleukin-17&#x02013;receptor antibody for psoriasis</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1181</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1109017</pub-id><pub-id pub-id-type="pmid">22455412</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Blauvelt</surname><given-names>A</given-names></name><name><surname>Papp</surname><given-names>KA</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Luger</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>M</given-names></name><etal/></person-group><article-title>UNCOVER-1 study group; UNCOVER-2 study group; UNCOVER-3 study group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1512711</pub-id><pub-id pub-id-type="pmid">27299809</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Buettner</surname><given-names>R</given-names></name><name><surname>Turkson</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name><name><surname>Muehlbeyer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>5998</fpage><lpage>6003</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409467102</pub-id><pub-id pub-id-type="pmid">15837920</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>TJ</given-names></name><name><surname>Grosso</surname><given-names>JF</given-names></name><name><surname>Yen</surname><given-names>HR</given-names></name><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Kortylewski</surname><given-names>M</given-names></name><name><surname>Albesiano</surname><given-names>E</given-names></name><etal/></person-group><article-title>An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>4313</fpage><lpage>4317</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.7.4313</pub-id><pub-id pub-id-type="pmid">17878325</pub-id></element-citation></ref></ref-list></back></article>